EZZ Life Science announces AGM outcomes, board leadership change

EZZ Life Science Holdings Limited (ASX: EZZ) announced the outcomes of its annual general meeting held on November 28, 2025. All resolutions presented were determined by poll.

Notably, resolution 2, concerning the re-election of Glenn Cross as a director, was withdrawn as Mr. Cross chose not to stand for re-election. The board acknowledged Mr. Cross's contributions, with company director and chief executive Mark Quinn assuming the role of interim chair.

Shareholders voted to adopt the remuneration report with 19,070,201 votes for (98.55%) and 281,248 votes against (1.45%). Approval for a 7.1A mandate (special resolution) also passed with 31,234,432 votes for (97.81%) and 697,963 votes against (2.19%).